211 related articles for article (PubMed ID: 18640111)
1. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
2. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Dekeyne A; Rivet JM; Gobert A; Millan MJ
Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
[TBL] [Abstract][Full Text] [Related]
3. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Kalkman HO; Loetscher E
Eur J Pharmacol; 2003 Feb; 462(1-3):33-40. PubMed ID: 12591093
[TBL] [Abstract][Full Text] [Related]
4. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation.
Sprouse JS; Reynolds LS; Braselton JP; Rollema H; Zorn SH
Neuropsychopharmacology; 1999 Nov; 21(5):622-31. PubMed ID: 10516958
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Markianos M; Hatzimanolis J; Lykouras L
Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
[TBL] [Abstract][Full Text] [Related]
8. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Ninan I; Kulkarni SK
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Hirose T; Uwahodo Y; Yamada S; Miwa T; Kikuchi T; Kitagawa H; Burris KD; Altar CA; Nabeshima T
J Psychopharmacol; 2004 Sep; 18(3):375-83. PubMed ID: 15358981
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
11. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Kapur S; Remington G
Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
[TBL] [Abstract][Full Text] [Related]
13. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
14. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
15. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
Gessa GL; Devoto P; Diana M; Flore G; Melis M; Pistis M
Neuropsychopharmacology; 2000 Jun; 22(6):642-9. PubMed ID: 10788763
[TBL] [Abstract][Full Text] [Related]
16. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation.
Heidbreder CA; Foxton R; Cilia J; Hughes ZA; Shah AJ; Atkins A; Hunter AJ; Hagan JJ; Jones DN
Psychopharmacology (Berl); 2001 Jul; 156(2-3):338-51. PubMed ID: 11549234
[TBL] [Abstract][Full Text] [Related]
17. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Westerink BH; de Boer P; de Vries JB; Kruse CG; Long SK
Eur J Pharmacol; 1998 Nov; 361(1):27-33. PubMed ID: 9851538
[TBL] [Abstract][Full Text] [Related]
19. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
Gleason SD; Shannon HE
Psychopharmacology (Berl); 1997 Jan; 129(1):79-84. PubMed ID: 9122367
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
